First dosing of patient in Phase III Clinical trial of Jiangsu Vcare's VC005 Tablets for Moderate-to-Severe Atopic Dermatitis
Published Time:
2024-12-30 17:36
Source:
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
About VC005
VC005 is a novel, potent, and highly selective new-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug reduces the inflammatory response and the activation of immune cells, making it clinically applicable for treating inflammatory and autoimmune diseases. Compared to Upadacitinib, a leading marketed drug in the same class, VC005 more selectively reduces JAK2 inhibitory activity (based on in vitro kinase assay results), potentially alleviating safety concerns associated with excessive JAK2 inhibition in clinical settings.
About Atopic Dermatitis
Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense itching, and eczematous rashes. The disease significantly impairs patients' quality of life. Epidemiologically, the global AD patient population is approximately 230 million, with an adult prevalence rate of 2%–8% in China, affecting over 70 million individuals. Among these, 67% are mild cases and 33% are moderate-to-severe. Frost & Sullivan predicts that the number of cases will grow at a compound annual growth rate (CAGR) of 1.7% from 2025 to 2030. Traditional treatments, such as glucocorticoids, are associated with numerous adverse reactions and limited long-term benefits, making disease control challenging. Meanwhile, topical JAK1 small-molecule targeted inhibitors, as non-glucocorticoid immunosuppressants, offer promising efficacy and safer choices for mild-to-moderate AD patients.
Related News
01
2023
/
11
Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.
View Details
11
2023
/
08
Recently, the second-generation selective JAK1 inhibitor VC005 Topical Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first topical skin dosing in a patient with mild-to-moderate atopic dermatitis（AD）.
View Details
21
2023
/
07
Recently, the second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first patient dosing in its Phase II clinical trial for moderate-to-severe atopic dermatitis (AD).
View Details
11
2023
/
07
Jiangsu Vcare Awarded "Jiangsu Provincial Science and Technology Award (Second Prize)"
In July, the Jiangsu Provincial Government announced the recipients of the 2022 Jiangsu Provincial Science and Technology Awards. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), as a participating unit, jointly completed the project New Pharmaceutical Cocrystal Technology and Its Industrial Application with the research team of Zhang Jianjun and Gao Yuan from China Pharmaceutical University.
View Details
04
2023
/
05
The second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), recently initiated its Phase II clinical study for ankylosing spondylitis (AS). On April 26th, the first patient was successfully dosed at Peking University People's Hospital. VC005 Tablet demonstrated favorable metabolic properties, safety, and tolerability in the completed Phase I clinical study.
View Details
21
2023
/
03
Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn